Academic Journal
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
| العنوان: | Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project |
|---|---|
| المؤلفون: | Marina Elena Cazzaniga, Antonio Ciaccio, Romano Danesi, Francois P. Duhoux, Corrado Girmenia, Kalhil Zaman, Henrik Lindman, Fabrizio Luppi, Dimitrios Mavroudis, Ida Paris, Ayodele Olubukola, Ahmed Samreen, Christian Schem, Christian Singer, Anton Snegovoy |
| المصدر: | Frontiers in Oncology, Vol 13 (2023) |
| بيانات النشر: | Frontiers Media S.A. |
| سنة النشر: | 2023 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | CDK 4/6 inhibitors, abemaciclib, ribociclib, palbociclib, diarrhea, liver toxicity and injury, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2234-943X |
| Relation: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/full; https://doaj.org/toc/2234-943X; https://doaj.org/article/b92d0fe6abaa453fb0590fe813591377 |
| DOI: | 10.3389/fonc.2023.1247270 |
| الاتاحة: | https://doi.org/10.3389/fonc.2023.1247270 https://doaj.org/article/b92d0fe6abaa453fb0590fe813591377 |
| رقم الانضمام: | edsbas.B9C321C8 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 2234943X |
|---|---|
| DOI: | 10.3389/fonc.2023.1247270 |